Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.

@article{citeulike:3292085, abstract = {Meropenem is a carbapenem antibiotic approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections, complicated intra-abdominal infections, and pediatric bacterial meningitis (in patients >or=3 months of age). In clinical trials, it also has shown efficacy as initial empirical therapy for the treatment of nosocomial pneumonia. Unlike other beta-lactam antibiotics, including third-generation cephalosporins, carbapenems have shown activity against extended-spectrum beta-lactamase-producing and AmpC chromosomal beta-lactamase-producing bacteria. Compared with imipenem, meropenem is more active against gram-negative pathogens and somewhat less active against gram-positive pathogens, and it does not require coadministration of a renal dehydropeptidase inhibitor. In most comparative trials, clinical and bacteriological response rates with imipenem and meropenem were similar. Compared with clindamycin/tobramycin, meropenem is associated with a reduced length of hospital stay and a shorter duration of therapy among patients with complicated intra-abdominal infections. Meropenem is well tolerated by children and adults and has an acceptable safety profile. Alternative meropenem dosing strategies for the optimization of outcomes are under investigation.}, address = {University of Texas Health Science Center, Houston, Texas, USA. john.mohr@cubist.com}, author = {Mohr, J. F.}, citeulike-article-id = {3292085}, doi = {10.1086/590065}, issn = {1537-6591}, journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America}, keywords = {meropenem}, month = {September}, posted-at = {2008-09-19 06:45:03}, priority = {2}, title = {Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.}, url = {http://dx.doi.org/10.1086/590065}, volume = {47 Suppl 1}, year = {2008} }

TY - JOUR ID - citeulike:3292085 L3 - citeulike-article-id:3292085 N2 - Meropenem is a carbapenem antibiotic approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections, complicated intra-abdominal infections, and pediatric bacterial meningitis (in patients >or=3 months of age). In clinical trials, it also has shown efficacy as initial empirical therapy for the treatment of nosocomial pneumonia. Unlike other beta-lactam antibiotics, including third-generation cephalosporins, carbapenems have shown activity against extended-spectrum beta-lactamase-producing and AmpC chromosomal beta-lactamase-producing bacteria. Compared with imipenem, meropenem is more active against gram-negative pathogens and somewhat less active against gram-positive pathogens, and it does not require coadministration of a renal dehydropeptidase inhibitor. In most comparative trials, clinical and bacteriological response rates with imipenem and meropenem were similar. Compared with clindamycin/tobramycin, meropenem is associated with a reduced length of hospital stay and a shorter duration of therapy among patients with complicated intra-abdominal infections. Meropenem is well tolerated by children and adults and has an acceptable safety profile. Alternative meropenem dosing strategies for the optimization of outcomes are under investigation. JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America SN - 1537-6591 AD - University of Texas Health Science Center, Houston, Texas, USA. john.mohr@cubist.com TI - Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. VL - 47 Suppl 1 KW - meropenem AU - Mohr, JF PY - 2008/09/15/ UR - http://dx.doi.org/10.1086/590065 ER -